The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 01, 2020

Filed:

Sep. 16, 2016
Applicant:

Immune Ventures Llc, Seattle, WA (US);

Inventors:

Raymond J. Tesi, Seattle, WA (US);

David Moss, Seattle, WA (US);

Assignee:

Immune Ventures LLC, Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/13 (2015.01); A61P 35/00 (2006.01); A61K 41/10 (2020.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 35/13 (2013.01); A61K 41/10 (2020.01); A61P 35/00 (2018.01); C12N 5/0646 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2315 (2013.01); C12N 2502/30 (2013.01);
Abstract

The disclosure concerns a method for cancer treatment by in vivo priming and activation of natural killer cells for achieving tumor cell lysis. The method includes introducing into a patient a priming tumor cell preparation (PTCP) derived from a first tumor cell line, which is irradiated to inactivate the first tumor cells or a membrane preparation thereof, the first tumor cells having known priming ligands on the membrane surface thereof. The patient's rest NK cells are contacted by the PTCP in vivo, resulting in primed NK cells, which are characterized by upregulation of CD69, shedding of CD16, or a combination of CD69+ and CD16−. These primed NK cells then contact second tumor cells, the cancer, and are configured to lyse and kill the second tumor cells.


Find Patent Forward Citations

Loading…